T he inflammatory bowel diseases (IBDs) are gastrointestinal (GI) disorders, which typically relapse and remit over the course of a lifetime. 1 Because of their chronicity and the nature of current interventions, these conditions can impact significantly on the health infrastructure of a country. 2 A 2011 systematic review concluded that the incidence of pediatric-onset IBD (which constitutes 5%-25% of all IBD 1 ) was rising globally. 3 This increase in disease burden is more than likely due to environmental causes as a dramatic change in incidence trend cannot solely be attributed to genetics. 4 Recent Australian data has shown that the incidence of Crohn's disease (CD) 5 and ulcerative colitis (UC) 6 has increased dramatically between the latter half of last century and the beginning of this one. A 2004 study found that the Canterbury region of New Zealand had, at the time, one of the highest documented incidence rates of CD in the world. 7 A recently-published follow-up study demonstrated a 1.6-fold increase in the incidence of IBD within the same geographical area over a 10-year period. 8 The only study of pediatric IBD in New Zealand was a national survey conducted in 2002 to 2003 through the New Zealand Paediatric Surveillance Unit. 9 This report concluded that the national incidence rate was low compared with rates found in Western Europe and North America and did not attempt to ascertain disease prevalence. 9 Indeed, there is a dearth of information pertaining to the prevalence of pediatric IBD, with a recent systematic review citing the absence of any true population-based data on this topic. 10 Prevalence data is an important determinant of the adequacy of health care service provision. 11 Furthermore, information on prevalence allows for nongovernmental organizations to sufficiently provide for, and advocate on behalf of, the subset of a population afflicted by a certain disease. 11 As opposed to period prevalence which describes the burden of disease over a specific time frame, point prevalence provides a snapshot in time. Period prevalence takes into account births, deaths, and new cases which occur within the studied time frame.
This study, part of the over-arching pediatric IBD in New Zealand (PINZ) study, aimed to delineate point prevalence of pediatric IBD nationally on June 30, 2015. The PINZ study also aims to document and publish prospectivelycalculated incidence rates on pediatric IBD in New Zealand, separately.
METHODS

Study Population
The inclusion criteria for this study consisted of having a diagnosis of IBD (according to universally-accepted criteria 12, 13 ), and being under 16 years of age on June 30, 2015. All included patients had to be resident in New Zealand. Relevant details on each patient were entered into a secure Microsoft Access database (Microsoft Office Professional Plus 2013, Redmond, WA).
Specific details included sex, date of birth, ethnicity and address, year of IBD diagnosis, diagnostic modalities used, most severe disease phenotype (classified according to the Paris modification of the Montreal classification system 14 ) , details on family history, and surgical intervention. In the case of family history, the affected person's degree of kinship with the patient was noted. Where more than one family member was affected by IBD, the closest degree of kinship was noted for the purposes of this study.
The ethnic group classifications used in this study are in keeping with the recognized major ethnic groups in New Zealand, namely European, Maori, Asian, Pacific peoples, and Middle Eastern/Latin American/African (MELAA). 15 Ethnicities were recorded based on how patients self-identified and/or the ethnicities of both parents. All relevant ethnicities were noted where more than one was applicable.
Approval for the PINZ study was obtained from the Health and Disability Ethics Committee (HDEC) of the Ministry of Health of New Zealand.
New Zealand
Situated in the South Pacific between 34 and 47 degrees latitude south, with a land mass similar to that of the United Kingdom, New Zealand is made up of the North Island and the South Island. 16 As of June 30, 2015, New Zealand's estimated resident population was 4.6 million. 16 New Zealand has a public health care system which provides nondiscretionary specialist-level care at no cost to citizens and permanent residents. In addition to that, private health care is available in some instances, at a cost.
Case Recruitment
Information on every pediatric patient with IBD in the South Island has been prospectively collected by one of the study authors (ASD) since 2009. A second database contained information on every patient diagnosed with IBD who was resident in Canterbury in 2004. 7 Both databases were searched for patients who met the inclusion criteria of the current study.
Further to that, a list of every patient seen and treated in Christchurch Hospital (which has the only pediatric gastroenterology unit in the South Island) between 1990 and 2015 with a clinically-coded diagnosis of either "Crohn's," "ulcerative colitis," "inflammatory bowel disease," or "IBD" or a slight variation of any of those was obtained. Beyond that, intestinal histology results between 1996 (when the Pathology department at Christchurch Hospital started using a computerized results system) and 2015 were sought on any patient aged 16 and under that contained the above-mentioned terms. To account for the bias of having a prospectively collected database since 2009, patients diagnosed from that year onward were also searched for using lists obtained from the clinical coding and histopathology departments. Using this approach, 93.4% of cases which ended up in the final numbers were able to be identified and this provided excellent internal validity of the study methodology employed.
All patients in the North Island with pediatric IBD are known to one of the pediatric gastroenterologists at Starship Children's Hospital. If they are resident in the Auckland region they are seen at Starship hospital or else by the Starship Hospital pediatric gastroeterologists at remote clinics held throughout the North Island. Each of the 4 Starship Hospital pediatric gastroenterologists compiled a list (based on a coded diagnosis of IBD or one of its subtypes) of every patient with IBD known to their service. This list comprised patients resident in Auckland and those who lived in other North Island locations.
Members of the New Zealand Society of Gastroenterology (NZSG) were informed of the PINZ study and invited to approach the authors if they had patients who met the study criteria. To account for patients who may be cared for solely in the private sector, every adult gastroenterologist and pediatric surgeon practicing in Christchurch and Canterbury, respectively, was contacted and informed about the current study. Also, clinicians with significant private practices in the North Island were also individually approached about the PINZ study. A response was obtained from every adult physician and surgeon approached as to whether or not they had young people meeting inclusion criteria for the present study in their care.
In every instance, electronic patient records were studied. Where there was any ambiguity, the hard-copy case notes were retrieved to ensure accuracy of data collection. This list was updated throughout the first half of 2015 as new diagnoses of pediatric IBD were made.
Data Analysis
The last New Zealand census was performed in 2013 by Statistics New Zealand. In years where no census is undertaken, estimated population data are made available. The estimated New Zealand population of people between 0 and 15 years of age on June 30, 2015 was obtained from Statistics New Zealand for the purposes of this study. These figures were broken down by sex and geographic region.
Point prevalence of pediatric IBD in New Zealand on June 30, 2015 was calculated for IBD, CD, UC, and inflammatory bowel disease unclassified (IBDU) with the number of existing diagnoses serving as the numerator and the population estimate for that year serving as the denominator. Rates are reported per 100,000 population.
All raw information was analyzed descriptively. Age ranges and follow-up period are given as median with relevant interquartile ranges. Exact binomial confidence intervals for the prevalence rates were calculated because of the low numbers in some groups. Categorical variables were compared using the unpaired t test, Mann-Whitney test or one-way analysis of variance Statistical significance was accepted if P , 0.05. All statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad Software, LaJolla, CA).
RESULTS
Point Prevalence of Pediatric IBD on June 30, 2015
On June 30, 2015, there were 212 children under the age of 16 years with IBD living in New Zealand. One hundred sixty-one (75.9%) of these cases had CD, of whom 4 were initially diagnosed with IBDU before a subsequent reclassification to CD. Of the remaining cases, 32 (15.1%) had UC; 3 of those patients were initially classified as IBDU. There were 19 (9.0%) patients categorized as IBDU on June 30, 2015. Incorporating the estimated population figure of 0 to 15 years olds in New Zealand on that date (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B507), the point prevalence of pediatric IBD was 21.7/100,000 (95% confidence interval, 18.9-24.8) people under the age of 16 years. The point prevalence of CD, UC, and IBDU, respectively, was 16.5/100,000 (14.0-19.2), 3.3/100,000 (2.2-4.6) and 1.9/100,000 (1.2-3.0), respectively.
Point Prevalence of Pediatric IBD in New Zealand by Region
On June 30, 2015, pediatric IBD was prevalent in every region in New Zealand (Fig. 1 ). The region with the highest point prevalence of pediatric IBD was Marlborough with 57.9/100,000 children, whereas the Bay of Plenty had the lowest prevalence rate of 1.5/100,000 children. There were significantly higher point prevalence rates in the South Island compared with the North Island (P ¼ 0.0052). The region with the highest prevalence rate in the North Island was Wellington (22.9/100,000 children), which had a lower prevalence of pediatric IBD than all but one of the regions in the South Island.
Sex Distribution of Pediatric IBD in New Zealand
There were 129 (60.6%) boys affected with IBD in New Zealand on June 30, 2015 giving a male to female ratio of 1.6:1. The male to female ratio of the CD, UC and IBDU cohorts were 1.8:1, 0.7:1 and 2.2:1, respectively. There were 103 males affected with CD, whereas there were 13 males affected with UC and 13 males with IBDU. There was no significant difference between the sexes for either pediatric IBD in total or any of its subtypes (P ¼ 0.24).
Age Distribution of Pediatric IBD in New Zealand
The median age of children and young people affected with IBD in the country on June 30, 2015 was 13.2 years (10.8-14.8 yrs). There was no significant difference in age distribution by sex (P ¼ 0.98). When categorized by IBD subtype, the median ages of included patients were 13.5 years (11.1-15.0 yrs), 12.2 years (9.6-13.8 yrs), and 12.7 years (9.5-14.0 yrs) for CD, UC, and IBDU, respectively. There was a significant difference between the median ages based on IBD subtype with post hoc testing revealing a significant difference between the median ages of the CD and IBDU, cohorts (P ¼ 0.0084).
Ethnic Distribution of Pediatric IBD in New Zealand
One hundred eighty-four (86.8%) of the 212 patients included in the prevalence cohort of the PINZ project were European. Of the remainder, 9 (4.2%) patients were Maori, 21 (9.9%) patients Asian, whereas 3 (1.4%) patients each were Pacific Islander and Middle Eastern. During the last national census in 2013, the proportion of European, Maori, Asian, Pacific Islander, and MELAA peoples were 74%, 15%, 12%, 7%, and 1%, respectively. 15 Family History of IBD Forty-six (21.7%) of the 212 patients with pediatric IBD in New Zealand on June 30, 2015 had a positive family history of IBD. In 21 cases, the affected family member was a first-degree relative, whereas in 9 cases the affected family member was a second-degree relative. In 15 cases, the affected family member was a third-degree relative or greater. In one case the relationship of the affected family member to the case was not able to be documented.
Investigation Modalities Used at the Time of Diagnosis
Complete diagnostic information was available on 211 (99.5%) of the 212 children with pediatric IBD in New Zealand on June 30, 2015. Of these, all had colonoscopy and 183 (86.7%) had an upper GI tract endoscopy at the time of diagnosis. One child was strongly suspected of having IBD at laparoscopy and this was confirmed at endoscopy shortly thereafter. Another patient was diagnosed and treated with steroids after sigmoidoscopy although diagnostic upper GI tract endoscopy and colonoscopy were performed within 6 months of initial endoscopy.
One hundred twenty (56.6%) of the 212 cases had dedicated small-bowel imaging at the time of initial endoscopic assessment, or within 6 months of a formal diagnosis. Eighty-five of these patients had magnetic resonance enterography (MRE), 29 had barium meal and follow through, 4 had capsule endoscopy, and one had a computed tomography abdomen, which provided adequate visualization of the small bowel. In one child, both magnetic resonance enterography and a barium meal and follow through had to be abandoned because of poor patient compliance.
Paris Classification of Pediatric IBD in New Zealand
Children with CD and UC were stratified according to the Paris classification system for pediatric IBD 14 (Table 1) .
Ileocolonic CD was the most common lower GI tract location with 87 (54%) of the included patients with CD affected. One hundred sixteen (72%) of the patients with CD had upper GI tract involvement, whereas 28 (17.4%) had perianal involvement. Most patients with CD had an inflammatory phenotype (n ¼ 145; 90.1%).
Twenty-one (65.6%) of the 32 cases with UC had pancolonic involvement (E4). There were 5 (15.6%) patients who had proctitis (E1), 4 (12.5%) who had left-sided colitis (E2), and 2 (6.3%) who had right-sided colitis (E3).
Surgery for Pediatric IBD in New Zealand
Among the children and young people under the age of 16 years with IBD in New Zealand on June 30, 2015, 31 (14.6%) had a history of surgery for their IBD. Of these, 26 had CD and 5 UC. The median period of follow-up of all patients included in the study, calculated as whole years between 1 January of the year of diagnosis and December 31, 2015, was 3 years (interquartile range [2] [3] [4] [5] .
Among the patients with CD who underwent IBDassociated surgery, 4 had an ileocolic resection, 3 had a smallbowel resection, 5 had partial colectomies, one patient had a defunctioning ileostomy without an intestinal resection, one had a gastrostomy placed for enteral nutrition, and 13 patients had perianal surgery involving drainage of an abscess, laying open of a fistula with seton placement or a combination of the 2. Each of the 5 cases with UC who underwent surgery had laparoscopic proctocolectomy with subsequent ileoanal pouch formation.
DISCUSSION
The current study has established that the national prevalence of pediatric IBD in New Zealand on June 30, 2015 was 21.7/100,000 (18.9-24.8). Furthermore, striking regional differences in prevalence were observed, with an overall gradient indicating greater rates in the south of New Zealand compared with the north.
The incidence of pediatric IBD is known to be increasing throughout the world. Much of the epidemiological data attesting to this has originated from Europe [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and North America. [27] [28] [29] [30] [31] Retrospective Australian studies have shown a large increase in the incidence of both CD 5 and UC 6 among the pediatric population in recent decades. Interval studies from the Canterbury region in New Zealand have shown an increasing rate of IBD over the period of one decade. 7, 8 The only previous study looking at pediatric IBD in New Zealand concluded that the national incidence of IBD was at the lower end compared with North America and the United Kingdom. 9 Point prevalence is a proportion which is obtained by dividing the number of people affected by a particular disease at a specific time point by the total number of people in that population group. 32 Measures of disease prevalence are a useful gauge of the (in)adequacies of health care resource provision. It provides a snapshot of the burden of a particular condition, within a defined population, at a specific time point.
In a systematic review conducted by Cameron et al, 10 prevalence rates for pediatric IBD are listed as being between 6.0 to 30.0/100,000 children. The abstract cited the lack of any true population-based studies and concluded from the available data that pediatric IBD prevalence was highest in North America and Europe. The data from the current study indicated that rates of IBD in children in NZ are at the higher end of this range.
A remarkable finding from this study is the north-south discrepancy between prevalence rates of pediatric IBD in New Zealand. The prevalence rates in 5 out of the 7 regions in the South Island are higher than the top-end of the range given in the 
This cohort included up to 16 years only. A1a, diagnosed under age 10 years; A1b, diagnosed between ages 10 to 17 years; B1, nonstricturing nonpenetrating; B2, stricturing; B3, penetrating; L1, ileal; L2, colonic; L3, ileocolonic; L4a, upper GI disease proximal to ligament of Trietz; L4b, upper GI disease distal to ligament of Trietz; n/a, not available and/or not assessed; p, perianal disease modifier.
aforementioned systematic review. 10 The PINZ study is based in Canterbury and this may account for a degree of underestimation of IBD cases identified in the North Island. However, because of the robust methodology used, the number of missed cases is likely to be small. Evidence from Europe and North America has shown a similar north-south gradient but in reverse-with geographical locations at higher latitude tending to have higher IBD burden. 4, [33] [34] [35] An American study found a higher occurrence of IBD in northern regions compared with more southern ones. 36 That study found that the frequency of IBD was also higher in urban areas when compared with rural ones. A prospective, multicentre European study published in 1991 also found that the incidence of IBD was higher in northern Europe compared with locations in the south of that continent. 35 Although neither study was able to identify causal factors as to the seeming correlation between higher latitudes and the higher incidence of IBD, some have suggested that the greater sunlight exposure in southern areas may be protective against the development of IBD via the vitamin D pathway. 33 Findings arising from the PINZ study are the first in the world to show higher prevalence rates in the southern part of a country compared with its northern counterpart. Rather than contradicting existing results, findings from the current study may reflect the important association between vitamin D (as a surrogate of sunlight exposure) and IBD. 37 Of note, however, is the fact that the percentage of New Zealanders who identify as European is higher along the more southern latitudes of the country. To illustrate the point, the proportion of New Zealanders who identify as European is 69.6% of the total population in the North Island, whereas that proportion is 88.2% in the South Island (personal communication, R Didham, Statistics New Zealand). Previous studies have shown that the rates of IBD among immigrant populations in Canada 38 and the United Kingdom 39 often exceed those of the native population and of those in the immigrants' country of origin. Although this study was unable to comment on the impact of immigration on the prevalence of IBD in New Zealand (if any), it is hoped that in time, data gathered as part of the PINZ study will be able to address that question.
The ratio of CD:UC:IBDU among the prevalent cohort was approximately 15:3:2. This suggests a significant predominance of CD over UC (and IBDU) in New Zealand; a ratio higher than has been demonstrated elsewhere. 40 There was also a male preponderance overall and within all subgroups except for UC, in keeping with the literature. 18, 22, [40] [41] [42] The predominance of ileocolonic CD and pan-colonic UC was, again, in keeping with pediatric IBD trends elsewhere described. 1, 22, 40, 41, 43 Only 86% of patients described in this study underwent upper GI tract endoscopy at the time of diagnosis. National guidelines clearly stipulate that upper GI tract endoscopy should be routinely performed as part of the work-up for IBD. 44 The reasons why this was not adhered to in every instance is not clear, although it is possible that adult gastroenterologists who made the diagnosis in some cases may not have been used to routinely performing upper GI tract endoscopy, as is often the case in the diagnosis of IBD among adult patients. Another point to note is the fact that dedicated small-bowel imaging was only performed in 56.6% of patients, within 6 months of diagnosis. The reason why this figure is not approaching 100% is again unclear although it is worth pointing out that MRE is often not attempted in patients less than 8 years, in New Zealand, and the use of barium meal and follow through is variable between pediatric gastroenterologists. It is worth noting that in some cases small-bowel imaging may have been organized later than 6 months after diagnosis. Also in cases of isolated distal colitis, routine small-bowel imaging is not required according to local guidelines.
Results from the present study serve to re-emphasize the importance of upper GI tract endoscopy and small-bowel imaging to ensure that a correct and complete diagnosis of IBD is made in every case and so that management can be appropriately tailored.
Cases of pediatric IBD managed locally, particularly in small centers, without any specialist (pediatric) gastroenterology input may not have been included in the PINZ database. Consensus among senior gastroenterologists in New Zealand, however, is that, that number is likely to be small. Taking into account that possible oversight, the prevalence rates here given might in fact be an underestimation. The study methodology used also consisted of robust case note review by a single observer (RNL) who also classified IBD phenotype-a method used elsewhere 18 and one which negates the risk of interobserver variation.
The results from the PINZ study represent the first, population-based, national prevalence rates of pediatric IBD and its subtypes. These results clearly show that the prevalence of pediatric IBD in New Zealand is significant and comparable with some of the highest rates in other places in the world. There are currently 5 full-time pediatric gastroenterologists in New Zealand, 4 of whom are based in Auckland, in the North Island. The gradient of increasing prevalence of pediatric IBD along lower latitudes in New Zealand would suggest that this work-force delineation may need modification. The economic burden of pediatric IBD which is typically more extensive and aggressive than adult-onset IBD 1 also bears consideration.
Prevalence rates provide a clear and present indication of the burden of disease within a society. These data can better inform health service provision, particularly for a relatively new subspecialty like pediatric gastroenterology. 45 The instances where disease incidence is thought to be increasing, point prevalence and prospectively collected incidence rates are pivotal pieces of information. The PINZ study hopes to answer both these questions in time.
